Increased mortality risks of pre-diabetes (impaired fasting glucose) in Taiwan

被引:93
作者
Wen, CP
Cheng, TYD
Tsai, SP
Hsu, HL
Wang, SL
机构
[1] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA
[2] Univ Texas, Hlth Sci Ctr, Houston, TX USA
关键词
D O I
10.2337/diacare.28.11.2756
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE - The objective of this article was to assess mortality risks at different levels of fasting blood glucose (FBG) in Taiwan, with particular attention to those pre-diabetic subjects with impaired fasting glucose (IFG). RESEARCH DESIGN AND METHODS - Governmental employees and schoolteachers were followed up for an average of 11 years. With the use of Cox regression analyses, mortality risks were calculated for 36,386 subjects, aged 40 - 69. RESULTS - FBG >= 110 mg/dl was associated with increased mortality risks for all causes, cardiovascular diseases (CVD), and diabetes. IFG, when defined as 110-125 mg/dl, was associated with a significant increase for CVD and/or diabetes mortality. These mortality risks remained elevated when known CVD risk factors were adjusted for. The IFG group shared risk factor characteristics more with the FBG >= 126 mg/dl group than with the FBG < 110 mg/dI group. When IFG was defined as 100-125 mg/dl, the number of subjects quadrupled, but mortality risks diminished substantially because of the inclusion of 100-109 mg/dl group. The lowest FBG group, 50-75 mg/dl, had a significant 2-fold risk from all causes. CONCLUSIONS - There was an overall J-shaped relationship between all-cause mortality and FBG. IFG, when defined as 110-125 mg/dl, is an independent risk factor and should be aggressively treated as a disease because its Subsequent mortality risks for CVD and diabetes were significantly increased. The newly defined IFG at 100-125 mg/dl did not have the predictive power for later increases in CVD or diabetes mortality.
引用
收藏
页码:2756 / 2761
页数:6
相关论文
共 53 条
[1]   Diabetes mellitus, impaired fasting glucose, atherosclerotic risk factors, and prevalence of coronary heart disease [J].
Alexander, CM ;
Landsman, PB ;
Teutsch, SM .
AMERICAN JOURNAL OF CARDIOLOGY, 2000, 86 (09) :897-902
[2]  
Amer Diabet Assoc, 2005, DIABETES CARE, V28, pS37
[3]  
American Diabetes Association, 2004, DIABETES CARE S1, V27, pS11, DOI DOI 10.2337/DIACARE.27.2007.S11
[4]  
[Anonymous], 1975, International Classification of Diseases
[5]   Is there glycemic threshold for mortality risk? [J].
Balkau, B ;
Bertrais, S ;
Ducimetiere, P ;
Eschwege, E .
DIABETES CARE, 1999, 22 (05) :696-699
[6]   High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men -: 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study [J].
Balkau, B ;
Shipley, M ;
Jarrett, RJ ;
Pyörälä, K ;
Pyörälä, M ;
Forhan, A ;
Eschwège, E .
DIABETES CARE, 1998, 21 (03) :360-367
[7]   Impaired glucose tolerance, but not impaired fasting glucose, is associated with increased levels of coronary heart disease risk factors - Results from the Baltimore Longitudinal Study on Aging [J].
Blake, DR ;
Meigs, JB ;
Muller, DC ;
Najjar, SS ;
Andres, R ;
Nathan, DM .
DIABETES, 2004, 53 (08) :2095-2100
[8]  
Borch-Johnsen K, 1999, LANCET, V354, P617
[9]   Glucose tolerance and cardiovascular mortality -: Comparison of fasting and 2-hour diagnostic criteria [J].
Borch-Johnsen, K ;
Neil, A ;
Balkau, B ;
Larsen, S ;
Nissinen, A ;
Pekkanen, J ;
Tuomilehto, J ;
Jousilahti, P ;
Lindstrom, J ;
Pyörälä, M ;
Pyörälä, K ;
Eschwege, E ;
Gallus, G ;
Garancini, MP ;
Bouter, LM ;
Dekker, JM ;
Heine, RJ ;
Nijpels, HG ;
Stehouwer, CDA ;
Feskens, EJM ;
Kromhout, D ;
Peltonen, M ;
Pajak, A ;
Eriksson, J ;
Qiao, Q .
ARCHIVES OF INTERNAL MEDICINE, 2001, 161 (03) :397-405
[10]  
Charles MA, 1996, LANCET, V348, P1657, DOI 10.1016/S0140-6736(05)65719-4